Rettig, W. J. & Old, L. J. Immunogenetics of human cell surface differentiation. Annu. Rev. Immunol.7, 481–511 (1989). ArticleCAS Google Scholar
Van den Eynde, B. J. & Scott, A. M. Encyclopedia of Immunology (eds Roitt, D. P. J. & Roitt, I. M.) 2424–2431 (Academic Press, London, 1998). Book Google Scholar
Scott, A. M. et al. A Phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptor. Proc. Natl Acad. Sci. USA104, 4071–4076 (2007). An important trial describing the antibody targeting of a unique tumour-specific conformational receptor epitope in cancer patients and highlighting the relevance of early phase clinical trial design in antibody development. ArticleCAS Google Scholar
Hughes, B. Antibody–drug conjugates for cancer: poised to deliver? Nature Rev. Drug Discov.9, 665–667 (2010). ArticleCAS Google Scholar
Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev. Immunol.10, 317–327 (2010). ArticleCAS Google Scholar
Nelson, A. L. et al. Development trends for human monoclonal antibody therapeutics. Nature Rev. Drug Discov.9, 767–774 (2010). ArticleCAS Google Scholar
Deckert, P. M. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets10, 158–175 (2009). ArticleCAS Google Scholar
Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev. Cancer.8, 579–591 (2008). ArticleCAS Google Scholar
Ravetch, J. In vivo veritas: the surprising roles of Fc receptors in immunity. Nature Immunol.11, 183–185 (2010). ArticleCAS Google Scholar
Schliemann, C. & Neri, D. Antibody-based vascular tumor targeting. Recent Results Cancer Res.180, 201–216 (2010). ArticleCAS Google Scholar
Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res.9, 1639–1647 (2003). CASPubMed Google Scholar
Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360, 1408–1417 (2009). ArticleCAS Google Scholar
Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39–51 (2007). ArticleCAS Google Scholar
Weiner, G. J. Rituximab: mechanism of action. Semin. Hematol.47, 115–123 (2010). ArticleCAS Google Scholar
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Eng. J. Med.363, 711–723 (2010). A pivotal Phase III trial that led to the approval of ipilimumab for the treatment of patients with metastatic melanoma. ArticleCAS Google Scholar
Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nature Rev. Immunol.10, 301–316 (2010). ArticleCAS Google Scholar
Cheson, B. D. & Leonard, J. P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med.359, 613–626 (2008). ArticleCAS Google Scholar
Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor–PI3K axis. Sci. Signal.2, ra31 (2009). Article Google Scholar
Canadas, I. et al. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin. Transl. Oncol.12, 253–260 (2010). ArticleCAS Google Scholar
Scartozzi, M. et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther.12, 361–371 (2010). CASPubMed Google Scholar
Vearing, C. et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signalling and downstream responses: potential as EphA3-specific tumour targeting reagents. Cancer Res.65, 6745–6754 (2005). ArticleCAS Google Scholar
Fox, N. L. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther.10, 1–18 (2010). ArticleCAS Google Scholar
Welt, S. et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol.12, 1193–1203 (1994). ArticleCAS Google Scholar
Jungbluth, A. A. et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl Acad. Sci. USA100, 639–644 (2003). ArticleCAS Google Scholar
Wu, A. M. & Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotech.23, 1137–1146 (2009). Article Google Scholar
Herbertson, R. A. et al. Phase I biodistribution and pharmacokinetic study of Lewis Y targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Can. Res.15, 6709–6715 (2009). ArticleCAS Google Scholar
Caron, P. C. et al. A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood83, 1760–1768 (1994). CASPubMed Google Scholar
Scott, A. M. et al. Specific targeting, biodistribution and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma — results of a Phase I trial. J. Clin. Oncol.19, 3976–3987 (2001). ArticleCAS Google Scholar
Scott, A. M. et al. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen. Clin. Cancer Res.13, 3286–3292 (2007). ArticleCAS Google Scholar
Divgi, C. R. et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl Cancer Inst.83, 97–104 (1991). ArticleCAS Google Scholar
Dijkers, E. C. et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther.87, 586–592 (2010). ArticleCAS Google Scholar
de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature467, 543–549 (2010). CASPubMed Google Scholar
Strevel, E. L. & Siu, L. L. Cardiovascular toxicity of molecularly targeted agents. Eur. J. Cancer45, 318–331 (2009). Article Google Scholar
Asnacios, A., Naveau, S. & Perlemuter, G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur. J. Cancer45, 332–342 (2009). Article Google Scholar
Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27, 4733–4740 (2009). ArticleCAS Google Scholar
Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26, 1626–1634 (2008). ArticleCAS Google Scholar
Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359, 1757–1765 (2008). An important study demonstrating the lack of efficacy of wild-type EGFR-specific antibody cetuximab in patients with colorectal cancer harbouringKRASmutations. This led to the approval of cetuximab only in patients with wild-typeKRAScolorectal cancer. ArticleCAS Google Scholar
Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26, 374–379 (2008). ArticleCAS Google Scholar
Leach, D. R., Krummel, M. F. & Allison J. P. Enhancement of antitumor immunity by CTLA-4. Science271, 1734–1736 (1996). The first report of the enhancement of antitumour immunity following CTLA4 blockade. ArticleCAS Google Scholar
Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med.363, 1812–1821 (2010). ArticleCAS Google Scholar
Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab–DM1, an antibody–cytotoxic drug conjugate. Cancer Res.68, 9280–9290 (2008). ArticleCAS Google Scholar
Heiss, M. M. et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer127, 2209–2221 (2010). ArticleCAS Google Scholar
Boland, W. K. & Bebb, G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther.9, 1199–1206 (2009). ArticleCAS Google Scholar
Chen, S. et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol.23, 1538–1547 (2005). Article Google Scholar
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J. Clin. Oncol.28, 3167–3175 (2010). ArticleCAS Google Scholar
Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science331, 1612–1616 (2011). ArticleCAS Google Scholar
Kirkwood, J. M. et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol.26, 3445–3455 (2008). ArticleCAS Google Scholar
Taylor, C. et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res.15, 5133–5143 (2007). Article Google Scholar
Pillay, V., Gan, H. K. & Scott, A. M. Antibodies in oncology. N. Biotech.28, 518–529 (2011). ArticleCAS Google Scholar
Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nature Rev. Immunol.10, 345–352 (2010). ArticleCAS Google Scholar
Pillay, V. et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Oncogene.11, 448–458 (2009). CAS Google Scholar
Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21, 3940–3947 (2003). This important study demonstrated the impact that FcγR polymorphisms have on the efficacy of rituximab in patients with follicular lymphoma, and highlights the importance of ADCC in the efficacy of rituximab. ArticleCAS Google Scholar
Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol.26, 1789–1796 (2008). ArticleCAS Google Scholar
Bibeau, F. et al. Impact of FcγRIIa–FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol.27, 1122–1129 (2009). ArticleCAS Google Scholar
Ferris, R. L., Jaffee. E. M. & Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol.28, 4390–4399 (2010). ArticleCAS Google Scholar